Ample Market Research has recently published a report Human Embryonic Stem Cells Market . The key objective of this report is to highlight various trends and dynamics, new and innovative technology and mergers and acquisitions that are expected to make a positive impact on the overall industry. This report studies the Human Embryonic Stem Cells market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report provides a detailed analysis of the prospects for the global Human Embryonic Stem Cells industry up to 2024, including an assessment of the impact of COVID-19.

To know How COVID-19 Pandemic Will Impact This Market/Industry -Request a sample copy of the report: https://www.amplemarketreports.com/sample-request/global-human-embryonic-stem-cells-market-1731516.html

Human Embryonic Stem Cells Market Latest Research Report 2018- 2025 covers a complete market structure across the world with a detailed industry analysis of major key factors. This report provides strategic recommendations consulted by the industrial experts including market forecasts, profit, supply, raw materials, manufacturing expenses, the proportion of manufacturing cost structure, latest market trends, demands and much more.

Global Human Embryonic Stem Cells Market is valued approximately USD XX billion in 2019 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2020-2026. Due to COVID-19 pandemic, the market is facing challenges because of government protocols to stay at home across the world. Human Embryonic Stem Cells (hESCs) are derived from blastocyst and are capable of differentiating into number of cell types that make up the human body as well as it replicates indefinitely and produce non-regenerative tissues such as neural and myocardial cells. They are used in treating a number of blood and genetic disorders related to the immune system, cancers, and disorders as well as used in investigational studies of early human development, genetic diseases and toxicology testing. The technological advancement involving stem cells therapy, rising demand for regenerative medicines, R&D in toxicology testing, technological advancements for the production of embryonic stem cells through alternative methods and increasing prevalence of genetic disorders are the few factors responsible for growth of the market over the forecast period. Furthermore, the introduction of innovative products and other strategic advancements by market players will create lucrative opportunities for the market. For instance, as per companys news release in January 2019, Stemcell Technologies Inc. launched mTeSRl Plus, an enhanced version of mTeSR1. mTeSR Plus is the stabilized feeder-free maintenance medium for human embryonic stem (ES) and induced pluripotent stem (iPS) cells. However, ethical concern related to stem cell research is the major factor restraining the growth of global Vegetable Chips market during the forecast period.

The regional analysis of global Human Embryonic Stem Cells market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. Asia Pacific is the leading/significant region across the world due to the presence of several prominent entities incorporated in the U.S. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2026.

This report discusses the key drivers influencing Human Embryonic Stem Cells market growth, demand, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on current and future development.

Human Embryonic Stem Cells market report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.

Key players analyzed in the Human Embryonic Stem Cells Insight Report: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell Technologies Inc., Biotime, Inc. / Cell Cure Neurosciences LTD, Thermo Fisher Scientific, Inc., CellGenix GmbH, ESI BIO, PromoCell GmbH, Lonza Group AG, Kite Pharma, Cynata Therapeutics Ltd.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Browse Detailed TOC, Tables, Figures, Charts And Companies Mentioned In Human Embryonic Stem Cells Market Research Report At: https://www.amplemarketreports.com/report/global-human-embryonic-stem-cells-market-1731516.html

Strategic Points Covered in Table of Contents

Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global Conductive Nylon market, years considered, and study objectives. Additionally, it touches the segmentation study provided in the report on the basis of the type of product and application.

Executive Summary: It gives a summary of key studies, viz. production, market growth rate, competitive landscape, market drivers, trends, and issues, and macroscopic indicators.

Production by Region: Here, the report provides information related to import and export, revenue, production, and key players of all regional markets studied.

Profile of Manufacturers: Each player profiled in this section is studied on the basis of SWOT analysis, their products, production, value, capacity, and other vital factors.

Market Size by Manufacturer

Consumption by Region

Market Size by Type,by Application

Production Forecast and Consumption Forecast

Industry Chain, Upstream, and Downstream Customers Analysis

Key Findings, Opportunities and Challenges, Threats, and Affecting Factors

Appendix

Get Complete Report in your Inbox within 24 hours Now at : https://www.amplemarketreports.com/buy-report.html?report=1731516&format=1

In the end, this report additionally presents product specification, producing method, and product cost structure. Production is separated by regions, technology, and applications. The Human Embryonic Stem Cells Market report includes investment come analysis and development trend analysis. The key rising opportunities of the fastest growing international Human Embryonic Stem Cells industry segments are coated throughout this report. This report provides information about the import, export, consumption and consumption value. The report then provides one of the most crucial aspects of the Human Embryonic Stem Cells Market the forecast for the next five to six years based on the previous as well as current data.

About Ample Market Research

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Attention to detail, consistency, and quality are elements we focus on. However, our mainstay remains to be knowledge, expertise, and resources to make us industry players.

Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Us

Ample Market Research & Consulting Private Limited

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: [emailprotected]

Website: http://www.amplemarketreports.com

Read more:
Excellent growth of Human Embryonic Stem Cells Market- Comprehensive study by key players: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell...

IPS Cell Therapy Comments Off on Excellent growth of Human Embryonic Stem Cells Market- Comprehensive study by key players: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell… | June 4th, 2020

BALTIMORE, June 4, 2020 /PRNewswire/ -- Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for its lead candidate, EXG34217, was approved on May 23, 2020. EXG34217 is an autologous cell therapy for telomere biology disorders with bone marrow failure.

The FDA's approval allows Elixirgen Therapeutics to proceed with its planned Phase I/II, open label, single center clinical trial to assess the safety and tolerability of EXG34217 at Cincinnati Children's Hospital Medical Center (ClinicalTrials.gov Identifier: NCT04211714). This program's treatment paradigm uses Elixirgen Therapeutics' proprietary ZSCAN4 technology to extend the telomeres of the hematopoietic stem cells of the patients.

About Elixirgen Therapeutics, Inc.Elixirgen Therapeutics, Inc. is a Baltimore-based biotechnology company co-founded by Akihiro Ko and Minoru Ko, MD, PhD, which is focused on curing humanity's ailments through innovations in stem cell biology.The company's experienced team of researchers has a wide variety of specialties, enabling it to use both basic and translational research approaches to developing therapies for genetic diseases and vaccines. For more information visit https://ElixirgenTherapeutics.com

Forward-Looking StatementsThis press release may contain "forward-looking" statements, including statements regarding the effectiveness of EXG34217 to treat telomere biology disorders with bone marrow failure and statements relating to the planned clinical trials of EXG34217. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in drug research and development. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Elixirgen Therapeutics that its plans and objectives regarding EXG34217 will be achieved. Any forward-looking statements in this press release speak only as of the date of this press release, and Elixirgen Therapeutics undertakes no obligation to update or revise the statementsin the future, even if new information becomes available.

Contact:Media RelationsElixirgen Therapeutics, Inc.(443) 869-5420Media@ElixirgenTherapeutics.com

See original here:
FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure - Herald-Mail Media

Bone Marrow Stem Cells Comments Off on FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure – Herald-Mail Media | June 4th, 2020

The current coronavirus pandemic clearly illustrates how dangerous viral infections can become for us. Independent of the present situation, there are people whose bodies are defenseless against infections because their immune systems are unable to combat them - they suffer from immunodeficiency diseases such as ADA-SCID (adenosine deaminase severe combined immunodeficiency) or Wiskott-Aldrich syndrome. Prof. Dr. Alessandro Aiuti, a physician and research scientist based in Milan who works at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) and at the Vita Salute San Raffaele University, is now being honored with the Else Krner Fresenius Prize for Medical Research 2020 for his groundbreaking successes in the development of gene therapies. The award is coupled to 2.5 million euros in prize money.

In the case of the rare immune disorder ADA-SCID, which exclusively afflicts young children and occurs about 15 times a year in Europe, a defective ADA gene within the genome disrupts lymphocyte development, leaving the young patient's body defenseless against infections. "Without effective therapy, the children rarely survive for more than 2 years because any infection can become perilous for them," Aiuti explains. Standard for this therapy is a bone marrow transplantation from a fully matched sibling. However, a suitable donor is available only for a minority of patients. "Meanwhile children with such a condition benefit from the advances we have made in the field of gene therapy. So far we have treated 36 children from 19 countries using the therapy we developed. In more than 80 percent of the cases, the treatment has had such an impact that no enzyme replacement therapy or transplantation is needed. This achievement has been made possible by the extraordinary effort and dedication of SR-Tiget researchers and clinical team throughout 25 years," Aiuti adds. All of the patients are still alive.

For these successes and his other work in the field of gene therapy, Alessandro Aiuti has now been honored with the Else Krner Fresenius Prize for Medical Research 2020 awarded by the Else Krner-Fresenius-Stiftung (EKFS) foundation. At 2.5 million euros, this award is one of the highest endowed prizes for medical research in the world. "Still young by comparison, this year the prize is being awarded for the third time. It honors research scientists for pioneering contributions in the areas of biomedical science. A major percentage of the prize money flows into the prizewinner's research and is supposed to contribute toward achieving further groundbreaking findings and medical breakthroughs in the future as well," emphasizes Prof. Dr. Michael Madeja, scientific director and member of the management board at EKFS.

The decision regarding the prize recipient was made by a ten-member international jury composed of renowned research scientists in the fields of genome editing and gene therapy along with delegates from the Scientific Commission at EKFS. Prof. Dr. Hildegard Bning, chairwoman of the jury and president of the European Society for Gene and Cell Therapy (ESGCT), substantiates the jury's decision: "Alessandro Aiuti is a truly outstanding physician and scientist. His work has decisively contributed to the development and successful treatment of rare, genetically caused disorders such as SCID. Thanks not least of all to the contributions he has made, even patients with other inheritable illnesses can presumably be treated successfully in the future."

After successful clinical trials, the gene therapy developed for ADA-SCID patients was approved as a pharmaceutical remedy in Europe. It is considered to be one of the key findings in the development of gene therapies worldwide. With this treatment certain blood stem cells (CD34+) are taken from the patient, then the cell DNA is modified. The cells are treated outside the body using a viral vector to accomplish this. The correct version of the gene for the ADA enzyme is introduced into the genome of the cells that were collected. The genetically modified cells are returned to the patient's bloodstream via intravenous infusion. A portion of the modified cells subsequently establish themselves in bone marrow again. The patient now has blood stem cells that function properly and produce lymphocytes to defend against infections - presumably on a life-long basis.

Alessandro Aiuti wants to utilize the prize money from EKFS to set the success story forth, to optimize the therapies further and map out the healing mechanisms involved in a better fashion. The scientist sees another major challenge in conveying the acquired knowledge beyond the successful gene therapies from Milan to as many other genetic disorders as possible. Alongside the therapy for ADA-SCID, the San Raffaele Telethon Institute for Gene Therapy has also developed gene therapies for four more hereditary diseases, among them the Wiskott-Aldrich syndrome and metachromatic leukodystrophy (MLD). To this day a total of more than 100 patients from 35 different countries have been treated.

Biography of Alessandro Aiuti

Alessandro Aiuti was born in Rome in 1966 and studied medicine there at Sapienza University. Following a stay at Harvard Medical School in Boston, Massachusetts in the USA, he received his doctorate in Human Biology in 1996 from Sapienza University. Since 1997 he has been active at the San Raffaele Scientific Institute in Milan, where he meanwhile also teaches as a professor at the Vita Salute San Raffaele University. He is furthermore Deputy Director of Clinical Research at the San Raffaele Telethon Institute for Gene Therapy and Head of the Pediatric Immunohematology Unit at San Raffaele Hospital.

Aiuti is the author of numerous and highly acclaimed publications. Over the course of his career he has received a number of prizes from national and international institutions. Aiuti is a member of the board of the European Society of Gene and Cell Therapy, and a member of the EMA Committee for Advanced Therapies since 2019.

The Else Krner Fresenius Prize for Medical Research

The international Else Krner Fresenius Prize for Medical Research came into existence in 2013 on the occasion of the 25th anniversary of Else Krner's death and is awarded in alternating fields of biomedical science. Endowed with 2.5 million euros, the prize is one of the most highly endowed medical research awards in the world. It honors and supports research scientists who have made significant scientific contributions in their fields and whose work can be expected to yield groundbreaking findings and medical breakthroughs in the future as well.

The Else Krner-Fresenius-Stiftung (EKFS) foundation - Advancing research. Helping people.

The Else Krner-Fresenius-Stiftung, a non-profit foundation, is dedicated to the funding of medical research and supports medical/humanitarian projects. The foundation was established in 1983 by entrepreneur Else Krner and appointed as her sole heir. EKFS receives virtually all of its income in dividends from the Fresenius healthcare group, in which the foundation is the majority shareholder. To date, the foundation has funded around 2,000 projects. With a current annual funding volume around 60 million euros the EKFS is one of the largest foundations for medicine in Germany. More information:www.ekfs.de.

The San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget)

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases. Over the years, the Institute has given a pioneering contribution to the field with relevant discoveries in vector design, gene transfer strategies, stem cell biology, identity and mechanism of action of innate immune cells. SR-Tiget has also established the resources and framework for translating these advances into novel experimental therapies and has implemented several successful gene therapy clinical trials for inherited immunodeficiencies, blood and storage disorders, which have already treated >115 patients and have led through collaboration with industrial partners to the filing and approval of novel advanced gene therapy medicines.

Fondazione Telethon

Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than EUR 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments. For more information, please visit:www.telethon.it

Issued by news aktuell/ots on behalf of Else Krner-Fresenius-Stiftung

See the original post here:
Groundbreaking Gene Therapies for Hereditary Diseases / Alessandro Aiuti, a physician and research scientist from Milan, receives the Else Krner...

Bone Marrow Stem Cells Comments Off on Groundbreaking Gene Therapies for Hereditary Diseases / Alessandro Aiuti, a physician and research scientist from Milan, receives the Else Krner… | June 4th, 2020

The need for medicines that help Covid-19 patients before the disease leaves the viral response phase and enters the host inflammatory phase has never been greater. While there are some positive signals in the prevention area, the most frequent estimates I am reading place a realistic timeline on the development of a vaccine of at least a year to eighteen months, and then global production capacity will need to ramp up.

There are two broad categories in the fight to treat Covid-19: 1) vaccines, 2) therapeutics.

There are at last count some 70 vaccine candidates in development. Some early promising signs have emerged from these groups of scientists, though we have also heard discouraging information, expressed even before this pandemic, that some viruses are notoriously difficult to vaccinate against, despite decades of work and billions of dollars. Even when a vaccine is developed, the complexities of production, distribution, and effectiveness present themselves. How long will the vaccine confer protection, and will mutations render it ineffective? How will we vaccinate enough of the 7.6 billion people on the planet to confer herd immunity? Assuming a vaccine that is effective, what about those who will invariably become infected nonetheless, either since they did not get vaccinated or since the vaccine isnt a 100% sure thing? After all, the flu vaccine is only 40% to 60% effective, according to the CDC.

There is an immediate need for therapeutics for Covid-19, and even after an effective vaccine is developed (and count me in the optimistic camp), there will be a huge continuing need for therapeutics.

[Source: The Journal of Heart and Lung Transplantation]

It is now generally recognized that the major cause of injury and death from Covid-19 is a condition called the cytokine storm [other research here, here and here]. I first learned about the cytokine storm about ten years ago from my research into a company named Cytosorbents (CTSO), which receives an honorable mention in my list of therapeutics contenders below.

Physicians Weekly describes the cytokine storm and its relationship to viruses like Covid-19 as follows:

A cytokine storm is an overproduction of immune cells and their activating compoundscytokineswhich, in something like a flu infection, is often associated with a surge of activated immune cells into the lungs. The resulting lung inflammation and fluid buildup can lead to respiratory distress and can be contaminated by a secondary bacterial pneumonia. This increases the risk of mortality in patientsCytokine storm is now seen as a likely major cause of mortality in the 1918-20 Spanish fluwhich killed more than 50 million people worldwide and the H1N1 swine flu and H5N1 bird flu of recent yearsand now COVID-19. [Source: Cytokine Storm: The Sudden Crash in Patients with COVID-19]

A number of public companies are currently testing their therapeutics for the ability to reduce the cytokine storm and thereby reduce mortality in Covid-19 patients. It is at the point when Covid-19 shifts from a viral disease to an immunological disease that the risk of death greatly increases, and I believe the below companies (in no particular order) have the best chance of producing an effective therapeutic.

Im going to give a brief description of each company and my understanding of its therapeutic candidate, followed by my reasons for owning the stock. Biotech investing is always tricky, where what works conceptually or in the lab might not work in a double-blind placebo controlled trial, and risk is compounded when multiple companies are racing to treat the same indication. For this reason, and because I have no secret insight into the method of action of these therapeutics, I own stock in each of these companies - a basket of therapeutics. I believe each of the companies that Ive selected as contenders has a compelling rationale and potential utility in multiple indications, which theoretically will reduce the investment risk of owning just one therapeutic in the event of failure to meet efficacy endpoints in Covid-19 trials.

Humanigen has a monoclonal antibody in trials for Covid-19. Humanigens drug is named Lenzilumab, and Lenzilumabs target is the Granulocyte macrophage - colony stimulating factor (GM-CSF).

According to Humanigen, Lenzilumab neutralizes GM-CSF, an upstream mediator of numerous inflammatory cytokines (or monokines as the case may be), such as MCP1, MIP1a, IL1b, IL6, TNFa, VEGF and IP10.

Humanigen states that many drugs that target an IL-6 blockade reduce only IL-6 and do not block inflammatory myeloid cells activation or downstream monokine production and that the IL-6 blockade alone has not shown clinical utility as a preventative measure in CAR-T induced cytokine stormmonokines such as MCP-1, MIP1a, MIG, IP10, IL-1 are important in the inflammatory cascade and only blocked with GM-CSF neutralization. [source: Humanigen Corporate Presentation]

[source: Humanigen Corporate Presentation]

On May 6, 2020, Humanigen announced that the first patient was dosed with Lenzilumab in a 238-participant Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia. The trial is recruiting at 8 sites so far as of May 27, including prestigious sites such as the Mayo Clinic (Phoenix, Arizona, Jacksonville, Florida, and Rochester, Minnesota branches), Emory University in Atlanta, and Dartmouth-Hitchcock in New Hampshire. Stanford University is also listed as a trial site.

In a press release announcing the initiation of this trial, Humanigens CEO Dr. Cameron Durrant stated, As the only company that has been working on prevention of cytokine storm through GM-CSF neutralization for nearly three years, we have published extensively in this field and filed extensive IP. We plan to bring this experience to the COVID-19 setting and recruit patients into this Phase III study as quickly as possible."

Humanigen also just announced on June 2 a raise of $72 million, with JPMorgan (JPM) acting as the placement agent, and investors in the raise include such biotech investment luminaries as Venrock Healthcare Capital Partners, Surveyor Capital, HealthCor, Valiant Capital Partners, First Light Asset Management and Ghost Tree Capital.

The CEO also stated that Humanigen plans to uplist onto a national securities exchange in the coming months.

A bit of history here: Humanigen was previously Nasdaq-listed, known as KaloBios (KBIO) and in 2015 planned to wind down operations for lack of funding. However, biotech investor, hedge fund manager, and now notorious target of worldwide scorn Martin Shkreli swooped in with an investor group and bought a controlling stake in the company. At the end of 2015, KaloBios appointed Shkreli as chairman of the board and elected him CEO. After only about a month, Shkreli was terminated as Chief Executive Officer of the Company and resigned the chairmanship. Owing to Shkrelis arrest and indictment, Nasdaq elected to delist KaloBios. After a Chapter 11 bankruptcy reorganization of the company and its emergence, the hiring of new management with no association with Shkreli, and the announcement that Shkreli sold his remaining stake in the companys stock, the companys fortunes have greatly improved. (For a guy with no official medical training and more than a few flaws, Shkreli does/did seem to have a good eye for promising drug candidates).

What I like about Humanigen:

HGEN

Market Cap:

Like Humanigen, CytoDyn also has a monoclonal antibody. CytoDyns is named Leronlimab, which also acts as an upstream modulator of numerous cytokines, among other therapeutic effects.

CytoDyn has recently applied for a BLA for Leronlimab, for use by HIV patients in combination. More recently, the company filed a request for expedited decision from the FDA. Leronlimab met its end points in a pivotal trial of patients with CCR5-tropic HIV-1 infection and documented genotypic or phenotypic resistance to HAART drugs within three drug classes or within two or more drug classes with limited treatment options.

Dr. Bruce K. Patterson, an advisor to CytoDyn and CEO of clinical lab IncellDx, analyzed the blood levels of numerous cytokines and other markers of 10 critically ill Covid-19 patients who were given Leronlimab under the FDAs Emergency Investigational New Drug (EIND) program, both before and after dosing, and determined that the CCR5 receptor binding and occupancy ability of Leronlimab appears to significantly reverse the course of the disease in the cases that were studied. Leronlimab appears to 1) reduce the cytokine storm, 2) modulate the bodys immune system to restore its effectiveness, and 3) reduce the viral load of Covid-19. Here is a study on which Dr. Patterson was corresponding author, entitled Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-1, authored with co-senior authors Lishomwa C. Ndhlovu, M.D., Ph.D. and Jonah B. Sacha, Ph.D.

Some key excerpts from this papers abstract:

Following compassionate care treatment with the CCR5 blocking antibody leronlimab, we observed complete CCR5 receptor occupancy on macrophage and T cells, rapid reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and a significant decrease in SARS-CoV-2 plasma viremia. Consistent with reduction of plasma IL-6, single-cell RNA-sequencing revealed declines in transcriptomic myeloid cell clusters expressing IL-6 and interferon-related genes. These results demonstrate a novel approach to resolving unchecked inflammation, restoring immunologic deficiencies, and reducing SARS-CoV-2 plasma viral load via disruption of the CCL5-CCR5 axis, and support randomized clinical trials to assess clinical efficacy of leronlimab-mediated inhibition of CCR5 for COVID-19.

The chemokine CCL5, also known as RANTES, being blocked from attaching to the CCR5 receptor by the presence of Leronlimab, is unable to summon more inflammatory cytokines when triggered by Covid-19, resulting in a reduction of inflammation and a possible reversal of the cytokine storm. According to Dr. Patterson's study,

Recent studies have found that a significant number of COVID-19 patients experience increased risks of strokes, blood clots and other thromboembolic events. Platelet activation, which leads to the initiation of the coagulation cascade, can be triggered by chemokines including CCL5 suggesting that leronlimab treatment may be beneficial beyond its immunomodulatory effects on inflammation and hemostasis in COVID-19 patients.

[Source: Pre-Print Study Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-1]

CytoDyn is currently enrolling patients in two blinded placebo controlled clinical trials, one Phase 2 75 patient trial in mild/moderate patients and one Phase 2b/3 390 patient trial in severe patients. The CEO said that as of June 2, 2020, the mild/moderate trial has 58 patients enrolled and they intend to unblind the trial on June 15 and hopefully reveal results by the end of June. The severe trial currently has 51 patients enrolled, and on June 15 the CEO said they also plan to do an interim look at the first 50 patients, which is built into the trial.

CytoDyn has given Leronlimab to 75 patients through the EIND protocol, and has reported many successful outcomes, though they point out that only controlled trials will confirm patient recoveries are due to the drugs efficacy.

CytoDyn is also conducting a breast cancer trial and a basket trial for the use of Leronlimab in various cancers. CytoDyn believes the unique CCR5 receptor occupancy method of action of Leronlimab is applicable to a wide variety of diseases.

CytoDyn is currently listed over-the-counter, though the CEO has stated as recently as June 2 that their plan is to uplist to a national securities exchange soon. I believe the company is currently extremely undercapitalized for all of their planned trials and indications, and will need to raise money in the very near term. CytoDyns stock price has risen dramatically along with the positive information about Leronlimab that has reached the public. Along with the extremely compelling results achieved by Leronlimab through the EIND process in Covid-19 patients and stories of lives saved, there are those who have criticized the CEO, Nader Pourhassan, Ph.D., for his statements about Leronlimab that some view as overly promotional (as well as what some consider rambling conference calls, and imprecise timelines.) Despite this, on the positive side, the CEOs philosophy appears to be: the more communication with the shareholder base, the better. The CEO has been with the company in various capacities since 2008, and you might love him or hate him. My take is to listen to the data and let it speak. I also was very impressed with interviews here and here, with Dr. Otto Yang, an HIV researcher at my alma mater U.C.L.A., who has been involved with EIND use of Leronlimab and the clinical trials of Leronlimab at U.C.L.A.

What I like about CytoDyn:

Clinical Trials:

Phase 2 Mild/Moderate 58 patients enrolled so far. 75 participants total.

Phase 2/3 Severe 51 patients enrolled so far. 390 participants total.

Chimerix owns the rights to a drug named dociparstat sodium, also known as DSTAT.

Chimerix describes DSTAT as

a glycosaminoglycan derivative of heparin with known anti-inflammatory properties, but with substantially reduced risk of bleeding complications compared to commercially available forms of heparin. DSTAT is currently in development as a first-line therapy in acute myeloid leukemia (AML). The scientific literature and recent clinical studies suggest that adding DSTAT to standard chemotherapy for AML may improve patient outcomes. [source: Chimerix Website]

Based on DSTATs target and method of action, Chimerix decided to rapidly initiate clinical trials for use in acute lung injury (ALI) in COVID-19 patients.

The company describes DSTATs compelling method of action in ALI as follows:

DSTAT has the potential to inhibit the hyperactive immune response and resulting inflammation, as well as address the underlying causes of coagulation disorders seen in COVID-19 patients, but with substantially reduced risk of bleeding complications compared to commercially available forms of heparin. Chimerix states that they anti-inflammatory effect of DSTAT occurs via the inhibition of high mobility group box 1 (HMGB1) activity. Inhibition of HMGB1 activity reduces expression of downstream proinflammatory cytokines including, but not limited to, IL-6, tumor necrosis factor- (TNF-), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1 (MIP-1), all of which are implicated in the overactive immune response seen in COVID-19. [source: Chimerix Website]

[source: Chimerix website]

DSTAT further could assist Covid-19 patients through reduction of hypercoagulation. Weve read about Covid-19 patients succumbing to strokes, as a result of blood clots.

Chimerix states that

Neutrophils are early responders to infection capable of extruding granular and nuclear contents to produce neutrophil extracellular traps (NETS). NETs may be beneficial (e.g., by trapping pathogens); however, excessive NETs can be pathogenic, particularly in the lungs where damage to the thin layer of cells in the alveoli can result in decreased oxygenation. HMGB1 promotes NETs which may drive hypercoagulation by providing a substrate for platelet aggregation and by upregulating tissue factors on endothelial cells. Activated platelets, in turn, release PF4, which further increases inflammation, creating a detrimental cycle. DSTATs inhibition of two key inflammatory drivers of this process (PF4 and HMGB1) may prevent and treat coagulation disorders observed in COVID-19 patients. [source: Chimerix Website]

Chimerix is currently conducting a clinical trial, summarized as A randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of DSTAT in patients with Acute Lung Injury (ALI) due to COVID-19. The trial aims to enroll 524 participants.

As of May 15, when the clinical trial was posted to clinicaltrials.gov, it had not yet begun recruiting, though in its May 7 earnings release, Chimerix stated its intention to have the trial up and running by the end of May, and to have the Phase 2 safety portion of the trial available before the end of the year.

I reached out to Chimerix to see if the company had also received EIND approval to treat Covid-19 patients with DSTAT, but I have not yet heard back.

What I like about Chimerix:

Clinical Trials:

Phase 2/3 / expected to have begun recruiting by end of May / 524 participants total

Mesoblast describes its technology as follows:

Mesoblasts proprietary mesenchymal lineage adult stem cells (MLCs) are found in multiple tissues where they play vital roles in maintaining tissue health. They are rare cells found around blood vessels that respond to signals associated with tissue damage; secreting mediators and growth factors which promote tissue repair and modulate immune responses.

For its Covid-19 treatments, Mesoblast is using Mesenchymal Stem Cells (MSCS) derived from its proprietary line. They are bone marrow derived and allogeneic.

Mesoblast gave its Remestemcel-L stem-cell infusions to 12 patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) in New York under the FDAs emergency compassionate use protocol, and the results were very impressive. Mesoblast reported that 9 of the 12 ventilator-dependent patients at Mt. Sinai were able to come off of the ventilators within a median of 10 days and were discharged from the hospital.

The company press release stated that the survival rate of these patients was 83%, versus only 12% survival of ventilator-dependent patients at two major hospitals in New York during the same March to April 2020 period in New York.

Mesoblasts 300 participant clinical trial in patients with moderate to severe ARDS from COVID-19 was announced on April 8, will enroll in up to 30 sites across North America, with planned interim analyses that may result in stopping the trial early for efficacy or futility.

The United States Food and Drug Administration (FDA) has accepted for priority review the Mesoblasts Biologics License Application (BLA) to seek approval of remestemcel-L for steroid-refractory acute graft versus host disease (SR-aGVHD) in children. The FDA set a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2020.

In addition to ARDS caused by Covid-19, Mesoblast is also testing remestemcel-L in graft vs. host disease, heart failure and chronic low back pain.

What I like about Mesoblast:

Clinical Trials:

Phase 3 / recruiting / 300 participants / First dosing May 6

Athersys is a leading developer of stem-cell based therapies, and their stem cell products are currently in advanced testing in the following indications: Covid-19 induced ARDS, Ischemic Stroke, Acute Myocardial Infarction, and HSC Transplant/GvHD.

Athersys unique value proposition is that their stem cell products, named MultiStem, are developed from stem cells called Multipotent Adult Progenitor Cells (which theyve trademarked as MAPC). These cells are distinct from mesenchymal stem cells. They acquire the cells initially from healthy adult bone marrow, and Athersys claims a proprietary method to culture and expand their stem cells that allows them to produce vastly more stem cell product on an industrial scale with ease and repeatability.

[source: Athersys Corporate Presentation]

Athersys announced their pivotal Phase 2/3 clinical trial of MultiStem in Covid-19 induced ARDS on April 13, 2020, and commenced patient enrollment on May 5. The study is designed to enroll approximately 400 subjects and will be conducted at leading pulmonary critical care centers throughout the United States.

What I like about Athersys:

Clinical Trials:

Phase 2/3 / recruiting / 400 participants / First enrollment May 5

Cytosorbents produces the cytosorb filter, a cartridge filled with adsorbent beads, and when placed in-line with a dialysis machine or hemoperfusion pump among other methods, can extract large quantities of inflammatory cytokines from the bloodstream of a patient to reduce the cytokine storm.

Cytosorb describes its filter as follows:

A CytoSorb cartridge is filled with CytoSorbents proprietary hemocompatible, porous polymer beads that are roughly the size of grains of salt. The dimensions of the pores in each bead are specifically designed so that large objects such as blood cells go around the bead while small objects like electrolytes pass through it. However, appropriately sized substances are captured and trapped inside the beads pores and channels via pore capture and surface adsorption and are permanently eliminated from blood. In particular, hydrophobic substances are preferentially adsorbed to the hydrophobic polymer beads. CytoSorb has been optimized to broadly remove many cytokines, toxins and other inflammatory mediators in the cytokine sweet spot, a 5-60 kDa molecular weight range where most cytokines reside. [Source:Cytosorbents Website]

[Source: Cytosorbents Press Kit]

The Cytosorb filter is also being used to extract drugs like blood thinners from a patients blood prior to heart surgery. Other potential uses include immunomodulation during CAR-T therapy, as CAR-T therapy has been well documented to sometimes cause cytokine release syndrome (CRS).

The Cytosorb filter is approved in Europe to treat the runaway inflammation of the cytokine storm, as a prophylaxis of said cytokine storm during open heart surgery, and to extract bilirubin in liver disease, and myoglobin in trauma.

On March 25, Dr. Phillip Chan, MD, Ph.D., the CEO of Cytosorbents, provided an update on the use of the Cytosorb filter to help patients with Covid-19. He stated,

CytoSorb has now been used in more than 70 COVID-19 patients to help treat cytokine storm and life-threatening complications such as acute respiratory distress syndrome (ARDS) and shock in Italy, China, Germany, and France. Due to the crisis, the ability to obtain patient level data has been very limited. However, based upon initial, preliminary verbal reports from physicians treating these complications, CytoSorb use has generally been associated with a marked reduction in cytokine storm and inflammation, improved lung function, weaning from mechanical ventilation, and a reversal of shock.

While Cytosorbents has had a long relationship with DARPA, the U.S. Army, the U.S. Department of Health and Human Services, and the National Institutes of Health (NIH), the Cytosorb filter has not yet received FDA approval for use in the United States, other than recent FDA Emergency Use Authorization in the United States for use in adult, critically-ill COVID-19 patients with imminent or confirmed respiratory failure.

The company sent out the following report to those on its email list in which a Milwaukee doctor talks about how the Cytosorb filter helped three of his critical Covid-19 patients: Could this blood filter not yet FDA approved save COVID-19 patients?.

I do not own stock in Cytosorbents currently, though I think their filter is useful and effective in many indications. Since they do not have an active FDA approved clinical trial in the works for Covid-19, I believe that other companies stand a good chance of being earlier to market with effective therapeutics for Covid-19.

Clinical Trials:

Not yet

Covid-19 Virus showing the "spike proteins" [image source: U.S. Centers for Disease Control]

The world needs an effective treatment for Covid-19, which has devastated economies and caused misery across the world. I decided to research the causes of the worst outcomes from Covid-19 infection, and locate the companies that I believe have the best chance of providing therapeutics to help mitigate the terrible effect this virus has wrought.

While I believe a vaccine will come, it may not be as soon as we hope (of course we hope we could have had it yesterday), and we are going to need therapeutics that ameliorate the cytokine storm and coagulation irregularities in the immediate term and even after a vaccine is developed. I think an effective therapeutic could potentially turn Covid-19 from an extremely dangerous virus into another bad flu, since symptomatic people, treated in time with a therapeutic that stops the cytokine storm, could escape the devastation of the bodys inflammatory cascade.

This article is my attempt to consolidate a couple months of research and selection of what I believe are viable therapeutics. I hope this research both inspires readers to do deeper research into the companies which I have highlighted, and generates active commentary where readers can suggest other Covid-19 therapeutics that they believe should be in any investors Covid-19 therapeutics basket.

Those familiar with my work know that normally I write single-stock research articles. In the case of Covid-19 therapeutics, Ive taken the multi-stock basket approach because I think it is the best way to deal with the inherent uncertainties involved in biotech. The only bright side that I can see from this pandemic (remember, Im an optimist) is that Covid-19 is calling attention to the cytokine storm, and companies around the world are throwing everything they have into researching treatments, which is accelerating human trials in an unprecedented way. If scientists can develop therapeutics to effectively settle our own immune systems down before they get out of control, we might find that this is a key to fighting not only Covid-19, but also many other intractable diseases.

Disclosure: I am/we are long ATHX, CMRX, CYDY, HGEN, MESO. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I am not registered as an investment advisor in the United States or in any other jurisdiction. Information in this article is presented as is, without warranty of any kind whether express or implied. I make no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. All expressions of opinion are subject to change without notice, and I do not undertake to update or supplement this report or any of the information contained herein.

This is not an offer to sell or a solicitation of an offer to buy any security, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction.

I have not received any form of compensation from the companies that I have written about in this article, nor have I received any form of compensation from company affiliates or other company shareholders.

Continued here:
COVID-19 Therapeutics: The Leading Contenders - Seeking Alpha

Bone Marrow Stem Cells Comments Off on COVID-19 Therapeutics: The Leading Contenders – Seeking Alpha | June 4th, 2020

Creating a tissue incubation system to help people with major tissue loss  CBS19 News

Read the rest here:
Creating a tissue incubation system to help people with major tissue loss - CBS19 News

Skin Stem Cells Comments Off on Creating a tissue incubation system to help people with major tissue loss – CBS19 News | June 4th, 2020

M3 Naturals Professional Peel Replaces Up to 6 Anti-Aging Skincare Products | Health.com Top Navigation Close View image

This M3 Naturals Anti-Aging Treatment Can Replace Up to 6 Products in Your Skincare Routine

this link is to an external site that may or may not meet accessibility guidelines.

See original here:
This M3 Naturals Anti-Aging Treatment Can Replace Up to 6 Products in Your Skincare Routine - Health.com

Skin Stem Cells Comments Off on This M3 Naturals Anti-Aging Treatment Can Replace Up to 6 Products in Your Skincare Routine – Health.com | June 4th, 2020

Follica plans to initiate its Phase 3 programme this year

PureTech Health plc (LSE: PRTC) (PureTech), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Follica, today announced positive feedback from an End of Phase 2 meeting with the US Food and Drug Administration (FDA) for its lead programme to treat male androgenetic alopecia. The company plans to advance the programme into Phase 3 development this year following the successful safety and efficacy optimisation study announced in December 2019.

Bharatt Chowrira, JD, PhD, president and chief of business and strategy at PureTech, said: This positive feedback from FDA enables Follica to move forward with its pivotal trial this year. Current treatments for the progressive hair loss caused by androgenetic alopecia are inadequate, and we are pleased with Follicas progress towards Phase 3 development, bringing us another step closer to a potential new treatment for the millions of people seeking safe, effective, non-surgical treatments to grow new hair.

The full text of the announcement from Follica is as follows:

Follica Announces Positive Feedback from End of Phase 2 Meeting with FDA for its Lead Programme to Treat Male Androgenetic Alopecia

Company plans to initiate its Phase 3 programme this year

BOSTON, June 4, 2020 -- Follica, Inc.(Follica), a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial ageing and other related conditions, today announced positive feedback from a meeting with the US Food and Drug Administration (FDA) as the company prepares to advance its lead programme into Phase 3 development following a successful safety and efficacy optimisation study for the treatment of hair loss in male androgenetic alopecia announced in December 2019.

Follica plans to launch its Phase 3 programme this year. Overall, approximately 280 patients will be enroled, with efficacy assessed against two co-primary endpoints: visible (non-vellus) hair count and patient-reported outcomes on a pre-established scale. The randomised, controlled, double-blinded studies will be conducted in multiple centers across the US. A maximal use study to further understand the pharmacokinetics of the treatment will be conducted in parallel. The trial design is consistent with feedback from the FDA during the End of Phase 2 meeting.

In the US alone, 47 million men are affected by progressive hair loss caused by androgenetic alopecia, a condition that is largely unresolved today, leaving many dissatisfied with the current available treatments and looking for a new alternative. Our recent safety and optimisation study points to a new level of effect, enabled by our proprietary approach, which stimulates the growth of new follicles and new hair, said Jason Bhardwaj, chief executive officer of Follica. Were grateful to the FDA for their guidance as we prepare for our pivotal programme, and we look forward to advancing the development of our treatment regimen, which has demonstrated strong potential to address the current need for those who seek treatment for androgenetic alopecia.

Follicas approach is based on generating an embryonic window in adult scalp cells via a series of short office-based treatments with its proprietary Hair Follicle Neogenesis (HFN) device. The scalp treatments, which last just a few minutes, stimulate stem cells and enable the growth of new hair follicles. A topical drug is then applied to enhance efficacy by growing and thickening new hair follicles and hair on the scalp.

Follica reported topline results from its safety and optimisation study in December 2019. That trial was designed to select the optimal treatment regimen using Follicas proprietary HFN device in combination with a topical drug and successfully met its primary endpoint. The selected treatment regimen demonstrated a statistically significant 44% improvement of visible (non-vellus) hair count after three months of treatment compared to baseline (p < 0.001, n = 19). Across all three treatment arms, the overall improvement of visible (non-vellus) hair count after three months of treatment was 29% compared to baseline (p < 0.001, n = 48), reflecting a clinical benefit across the entire trial population and a substantially improved outcome with the optimal treatment regimen. Additionally, a prespecified analysis comparing the 44% change in visible (non-vellus) hair count to a 12% historical benchmark set by approved pharmaceutical productsestablished statistical significance (p = 0.005).

In addition to the safety and optimisation study, Follica has validated its approach in prior clinical studies using prototype HFN devices with different treatment parameters and therapeutic compounds. Follicas translational work builds on research by George Cotsarelis, MD, who isolated and characterised the expression pattern of stem cells from a critical region of the follicle. An expert in epithelial stem cell biology, Dr Cotsarelis is chair of the department of dermatology at the University of Pennsylvania and a co-founder of Follica.

About Androgenetic Alopecia

Androgenetic alopecia represents the most common form of hair loss in men and women, with an estimated 90 million people who are eligible for treatment in the United States alone. Only two drugs, both of which have demonstrated a 12% increase of non-vellus hair count over baseline for their primary endpoints, are currently approved for the treatment of androgenetic alopecia1. The most effective current approach for the treatment of hair loss is hair transplant surgery, comprising a range of invasive, expensive procedures for a subset of patients who have enough donor hair to be eligible. As a result, there remains a significant need for safe, effective, non-surgical treatments to grow new hair.

About Follica

Follica is a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial ageing and other related conditions. Founded by PureTech (LSE: PRTC), a co-inventor of the current platform, and a group of world-renowned experts in hair follicle biology and regenerative medicine, Follicas experimental treatment platform has been shown to stimulate the development of new hair follicles and hair in three previously conducted clinical studies. The companys proprietary treatment is designed to induce an embryonic window via a device with optimised parameters to initiate hair follicle neogenesis, the formation of new hair follicles from epithelial (skin) stem cells. This process is enhanced through the application of a topical compound. Follica completed a safety and efficacy optimisation study in 2019, and its Phase 3 programme in male androgenetic alopecia is expected to begin in 2020. Follicas technology is based on work originating from the University of Pennsylvania that has been further developed by Follicas internal programme. Follicas extensive IP portfolio includes IP exclusively licensed from the University of Pennsylvania as well as Follica-owned IP.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTechs Founded Entities, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Companys unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

Read more:
PureTech Founded Entity Follica Announces Positive Feedback from FDA as it Prepares to Advance its Lead Programme in Male Androgenetic Alopecia into P...

Skin Stem Cells Comments Off on PureTech Founded Entity Follica Announces Positive Feedback from FDA as it Prepares to Advance its Lead Programme in Male Androgenetic Alopecia into P… | June 4th, 2020

BOSTON--(BUSINESS WIRE)--Follica, Inc. (Follica), a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial aging and other related conditions, today announced positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase 3 development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia announced in December 2019.

Follica plans to launch its Phase 3 program this year. Overall, approximately 280 patients will be enrolled, with efficacy assessed against two co-primary endpoints: visible (non-vellus) hair count and patient-reported outcomes on a pre-established scale. The randomized, controlled, double-blinded studies will be conducted in multiple centers across the U.S. A maximal use study to further understand the pharmacokinetics of the treatment will be conducted in parallel. The trial design is consistent with feedback from the FDA during the End of Phase 2 meeting.

In the U.S. alone, 47 million men are affected by progressive hair loss caused by androgenetic alopecia, a condition that is largely unresolved today, leaving many dissatisfied with the current available treatments and looking for a new alternative. Our recent safety and optimization study points to a new level of effect, enabled by our proprietary approach, which stimulates the growth of new follicles and new hair, said Jason Bhardwaj, chief executive officer of Follica. Were grateful to the FDA for their guidance as we prepare for our pivotal program, and we look forward to advancing the development of our treatment regimen, which has demonstrated strong potential to address the current need for those who seek treatment for androgenetic alopecia.

Follicas approach is based on generating an embryonic window in adult scalp cells via a series of short office-based treatments with its proprietary Hair Follicle Neogenesis (HFN) device. The scalp treatments, which last just a few minutes, stimulate stem cells and enable the growth of new hair follicles. A topical drug is then applied to enhance efficacy by growing and thickening new hair follicles and hair on the scalp.

Follica reported topline results from its safety and optimization study in December 2019. That trial was designed to select the optimal treatment regimen using Follicas proprietary HFN device in combination with a topical drug and successfully met its primary endpoint. The selected treatment regimen demonstrated a statistically significant 44% improvement of visible (non-vellus) hair count after three months of treatment compared to baseline (p < 0.001, n = 19). Across all three treatment arms, the overall improvement of visible (non-vellus) hair count after three months of treatment was 29% compared to baseline (p < 0.001, n = 48), reflecting a clinical benefit across the entire trial population and a substantially improved outcome with the optimal treatment regimen. Additionally, a prespecified analysis comparing the 44% change in visible (non-vellus) hair count to a 12% historical benchmark set by approved pharmaceutical products established statistical significance (p = 0.005).

In addition to the safety and optimization study, Follica has validated its approach in prior clinical studies using prototype HFN devices with different treatment parameters and therapeutic compounds. Follicas translational work builds on research by George Cotsarelis, M.D., who isolated and characterized the expression pattern of stem cells from a critical region of the follicle. An expert in epithelial stem cell biology, Dr. Cotsarelis is chair of the department of dermatology at the University of Pennsylvania and a co-founder of Follica.

About Androgenetic AlopeciaAndrogenetic alopecia represents the most common form of hair loss in men and women, with an estimated 90 million people who are eligible for treatment in the United States alone. Only two drugs, both of which have demonstrated a 12% increase of non-vellus hair count over baseline for their primary endpoints, are currently approved for the treatment of androgenetic alopecia1. The most effective current approach for the treatment of hair loss is hair transplant surgery, comprising a range of invasive, expensive procedures for a subset of patients who have enough donor hair to be eligible. As a result, there remains a significant need for safe, effective, non-surgical treatments to grow new hair.

About FollicaFollica is a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, epithelial aging and other related conditions. Founded by PureTech (LSE:PRTC), a co-inventor of the current platform, and a group of world-renowned experts in hair follicle biology and regenerative medicine, Follicas experimental treatment platform has been shown to stimulate the development of new hair follicles and hair in three previously conducted clinical studies. The companys proprietary treatment is designed to induce an embryonic window via a device with optimized parameters to initiate hair follicle neogenesis, the formation of new hair follicles from epithelial (skin) stem cells. This process is enhanced through the application of a topical compound. Follica completed a safety and efficacy optimization study in 2019, and its Phase 3 program in male androgenetic alopecia is expected to begin in 2020. Follicas technology is based on work originating from the University of Pennsylvania that has been further developed by Follicas internal program. Follicas extensive IP portfolio includes IP exclusively licensed from the University of Pennsylvania as well as Follica-owned IP.

1 Olsen EA et al, J Am Acad Dermatol. 2002 Sep;47(3):377-85Olsen EA et al, J Am Acad Dermatol. 2007 Nov;57(5):767-74. Epub 2007 Aug 29Price VH et al, J Am Acad Dermatol. 2002 Apr;46(4):517-23Kaufman et al, J Am Acad Dermatol. 1998 Oct; 39(4):578-589

Here is the original post:
Follica Announces Positive Feedback From End of Phase 2 Meeting With FDA for Its Lead Program to Treat Male Androgenetic Alopecia - Business Wire

Skin Stem Cells Comments Off on Follica Announces Positive Feedback From End of Phase 2 Meeting With FDA for Its Lead Program to Treat Male Androgenetic Alopecia – Business Wire | June 4th, 2020

For Australias balding community, letting your hair down is just an idiom.

But soon, it may be a reality.

In a breakthrough in the battle against baldness, researchers from the University of Pennsylvania have managed to grow skin that develops distinct layers, including hair follicles,from stem cells.

Scientists were already able to grow skin cells, but recreating the complex, multi-layered skin structure has been a major challenge.

As the largest human organ, the skin has multiple functions including temperature regulation and bodily fluid retention to the sensing of touch and pain that increases the difficulty of synthesising it, researchers say.

But over a four-to-five month period, researchers succeeded in growing complex skin cells and hair follicles, which were grafted onto mice.

More than half of the mice sprouted hair from the process.

Its a development that may also affect those with genetic skin disorders and cancers, as well as those with burns or wounds.

But those who are a little thin on the top shouldnt get excited too fast.

There are several major questions that remain before this approach can become a reality, researchers Leo Wang and George Cotsarelis say.

Several other aspects of the authors approach will also need to be optimised before it can move to the clinic.

The hairs that grew in the current study were small; in future, furtheroptimisation of culture conditions will be needed to form large scalp hairs.

However, the authors conclude: The work holds great promise of clinical translation we are confident that research will eventually see this promise realised.

See original here:
Eradicating balding a step closer with new procedure in the cross hairs - The New Daily

Skin Stem Cells Comments Off on Eradicating balding a step closer with new procedure in the cross hairs – The New Daily | June 4th, 2020

Retinol, sometimes referred to collectively as retinoids (the group name for everything in the retinol family) are powerful enough to fade hyper-pigmentation, soften wrinkles and give your skin some of that youthful glow back. Depending on the formulation, retinol formulations might even prevent future wrinkles. Since retinols have a reputation for being strong, some people are scared to actually start using them, or dont know how to begin choosing thebest retinol creamsfor their skin.

But with Google searches for retinol at an all-time high, we have a hunch that people are looking to improve the quality of their skinso weasked Austin-based dermatologist Dr. Adam Mamelak for a primer on all these ingredients starting with r (retinol, retinoids and retinoic acid) which all serve the same purpose.

According to Dr. Mamelak, in its most basic form, retinol is a form of vitamin A and has been used to treat acne, but it has also been shown to help decrease wrinkles and fine lines. More than that, retinol allows the skin to repair any damage already inflicted. And since its all powered by vitamin A, retinol helps turn over the skin, exfoliating it naturally, and also helps stimulate collagen production in the deeper layers.

As you begin your search for the right retinol for your skin, consider starting with one of these 10 options.

Unlike many retinol-based products, First Aid Beauty FAB Skin Lab Retinol Eye Cream With Triple Hyaluronic Acidis a light and creamy formula that doesnt sting. Its active ingredient is microencapsulated retinol, which means its surrounded by a protective layer that helps stimulate natural collagen production to minimize the appearance of crows feet, fine lines and and wrinkles without the irritation. ($42, Sephora.com).

No7 ADVANCED Retinol 1.5% Complex Night Concentrate was so eagerly anticipated in the UK that 100,000 people signed up for the waiting list. In addition to a high concentration of retinol, this product also has a retinol optimizer, which ensures that the product works throughout the night, along with a retinol soother to keep skin calm. ($36.99, us.no7beauty.com)

InstaNaturals Retinol Moisturizercontains a robust blend of ingredients designed to address multiple signs of aging. Combined with vitamin C, Hyaluronic Acid, nourishing oils and extracts, this moisturizer aims to smooth lines and wrinkles while reducing discoloration and blemishes on the skin. It works to fight breakouts by clearing away dead skin cells that can clog the pores, and brightens the appearance of discoloration. For best results, apply this product nightly and follow with an SPF during the day. ($24.00, InstaNaturals Retinol Moisturizer, Amazon.com)

Related: Your 10-Minute Makeup Guide to Looking Great on Your Next Zoom Work Call

This past year, Olay launched their Regenerist Retinol24 Night Collection, which hydrates, minimizes pores and evens your skin tone without irritation. The formulation combines retinol and the popular skincare ingredient Niacinamide (vitamin B3), which is used as a soothing ingredient in many acne and rosacea treatments. ($28.99,Olay.com).

If youre looking for a vegan option, Drunk ElephantsA-Passioni Retinol Anti-Wrinkle Creamis a good place to start. It combines 1.0% vegan retinol with other natural, soothing ingredientskale leaf extract and winter cherry juice make the list. ($78, Amazon.com)

If youve tried retinol in the past and had bad side effects including skin irritation,DefenAgemay be a good option for you. Its a clean beauty line, meaning there are no animal or human-originated ingredients, parabens, sulfates, mineral oils, or phthalates. This retinol substitute works by activating dormant LGR6+ stem cells in the body to create fresh new skin, meaning its active ingredients (which include a safe retinol substitute) encourage cell turnover in skin cells that have become sluggish due to the natural aging process. ($28.50 for the 24-Hour Fast Starter Kit, defenage.com)

RoC Skincares new Retinol Correxion Line Smoothing Night Serum Capsules. This overnight renewal treatment comes in single-use capsules (30 per jar), that are sealed for optimal ingredient freshness. Theyre also biodegradable, so you dont have to worry about extra waste. ($33.00, Ulta/Ulta.com)

SeneGence Advanced SenePlex+ Renewal Serum with Retinolcontains incredibly gentle ingredients, including meadowfoam seed oil, aloe vera and hyaluronic acid, so your skin isnt dry or irritated like with typical retinoids. Use two pumps at night for best results. ($75.00, seneweb.senegence.com)

Related: Your Guide to Buying Prescription Glasses Online

Recently, theres been a lot of buzz around an ingredient called bakuchiol (pronounced buh-koo-chee-all) which is derived from an Indian plant and is deeply hydrating.Ole Henriksen Goodnight Glow Retin-ALT Sleeping Creme uses bakuchiol, along with other gentle ingredients, that will leave your skin with a glowy look without redness or inflammation. ($55.00, Sephora.com)

Celebrity interviews, recipes and health tips delivered to yourinbox.

If youre a bit worried about trying retinol, you can always use a product once a week until your skin gets used to it. Or, ease yourself in with a body lotion instead. Advanced Clinicals Retinol Cream is great for elbows, feet, or other rough body parts in need of some extra attention. ($27.95, Walmart.com)

As Dr. Mamelak explains it, the reason retinol works so well is because it increases the blood flow to the skin which will ultimately improve collagen production.

He adds that when retinol is applied directly to the skin, the basal cells (the ones at the lowest level of the skin) will start to divide. This division activates new epidermal cells to migrate to the skin surface, he says. In more basic terms, this means that newer cells appear on the surface of skin, while older cells are shed causing the exfoliation process to occur.

All this improved collagen production and increased exfoliation comes with a bit of a priceyou might notice, for example, that your skin is more sensitive. As Dr. Mamelak explains it, Because the skin cells are rapidly producing, they lack the adhesion and lipid production to protect the skin. Without these layers of protection, your skin becomes more sensitive when using retinol. Your skin also becomes much more sensitive to sunlight, so Dr. Mamelak says using products containing SPF is mandatory when using retinol.

Next up, how to do your eyebrows.

Continue reading here:
Best Retinol Creams: Best Retinol Eye Creams, Night Creams and More - Parade

Skin Stem Cells Comments Off on Best Retinol Creams: Best Retinol Eye Creams, Night Creams and More – Parade | June 4th, 2020

Cosmetic Skin CareMarketBusiness Insights and Updates:

The latest Marketreport by a Data Bridge Market Researchwith the title[Global Cosmetic Skin CareMarket Industry Trends and Forecast to 2026].The new report on the worldwide Cosmetic Skin CareMarketis committed to fulfilling the necessities of the clients by giving them thorough insights into the Market. The various providers involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.The reports provide Insightful information to the clients enhancing their basic leadership capacity identified.Exclusive information offered in this report is collected by analysis and trade consultants.

Global cosmetic skin care market is set to witness a substantial CAGR of 5.5% in the forecast period of 2019- 2026.

Cosmetic skin care is a variety of products which are used to improve the skins appearance and alleviate skin conditions. It consists different products such as anti- aging cosmetic products, sensitive skin care products, anti- scar solution products, warts removal products, infant skin care products and other. They contain various ingredients which are beneficial for the skin such as phytochemicals, vitamins, essential oils, and other. Their main function is to make the skin healthy and repair the skin damages.Get PDF Samplecopy(including TOC, Tables, and Figures) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cosmetic-skin-care-market

Thestudy considers the Cosmetic Skin CareMarketvalue and volume generated from the sales of the following segments:Major Marketmanufacturerscovered in the Cosmetic Skin CareMarketare:LOral, Unilever, New Avon Company, Este Lauder Companies, Espa, Kao Corporation, Johnson & Johnson Services, Inc., Procter & Gamble, Beiersdorf, THE BODY SHOP INTERNATIONAL LIMITED, Shiseido Co.,Ltd., Coty Inc., Bo International, A One Cosmetics Products, Lancme, Clinique Laboratories, llc., Galderma Laboratories, L.P., AVON Beauty Products India Pvt Ltd, Nutriglow Cosmetics Pvt. Ltd, Shree Cosmetics Ltd

Segmentation:Global Cosmetic Skin Care Market

By Product

By Application

By Gender

By Distribution Channel

Get Table of Contents with Charts, Figures & Tables @https://www.databridgemarketresearch.com/toc/?dbmr=global-cosmetic-skin-care-market

Based on regions, the Cosmetic Skin CareMarketis classified into North America, Europe, Asia- Pacific, Middle East & Africa, and Latin AmericaMiddle East and Africa (GCC Countries and Egypt)North America (United States, Mexico, and Canada)South America(Brazil, Argentina etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Market Drivers:

Market Restraints:

Key Developments in the Market:

Key Benefits for Cosmetic Skin CareMarket:

Enquire Here For Discount Or Cosmetic Skin CareMarket Report Customization@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cosmetic-skin-care-market

About Us:Data Bridge Marketresearch endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process Data Bridge set forth itself as an unconventional and neoteric Marketresearch and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best Marketopportunities and foster efficient information for your business to thrive in the Market.We ponder into the heterogeneous Markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the Markettrends. Data Bridge delves into the Markets across Asia, North America, South America, Africa to name few.

Contact Us:Data Bridge MarketResearchUS: +1-888-387-2818UK: +44 208 089 1725Hong Kong: +852 819+2 7475Email: [emailprotected]

View post:
Future Growth of Cosmetic Skin Care Market by New Business Developments, Top Companies and Forecast to 2026 - Bulletin Line

Skin Stem Cells Comments Off on Future Growth of Cosmetic Skin Care Market by New Business Developments, Top Companies and Forecast to 2026 – Bulletin Line | June 4th, 2020

Our relationship to Neanderthals has been a point of contention for over a century. It all began with an inaccurate reconstruction of the first Neanderthal ever found, which portrayed them as brutish, stooped-over cavemen (turns out, that Neanderthal was an injured old man with arthritis).

But within the last half century, scientists have noticed the many biological and behavioral similarities that show just how close our species are. While these similarities are clear from hard objects like bones and tools, perishable objects, which comprise the majority of material culture items in humans, have been lacking.

Now, scientists have discovered a Neanderthal feat that hammers another nail in the coffin of supposed Neanderthal inferiority. Last month, an international team of researchers found a small section of a twisted cord attached to a stone flake in Neanderthal site in southeastern France, dated to over 40,000 years old. This constitutes the oldest direct evidence of fiber technology ever found.

A stone flake with three distinct twisted fibers preserved (indicated by the box).

M.-H. Moncel

When artifacts are recovered from archaeological sites, they are generally imaged using high powered microscopes to zoom in on tiny marks and details on the stones. Previously, plant fibers had been found on stones at this site, but they were too poorly preserved to be interpreted. When the team examined this particular flake, they were surprised to find three distinct twisted fibers, which were then twisted together in the opposite direction to form a 3-ply cord.

While it may not sound like much, this piece of string hints at something much more significant. For one, extracting and manipulating plant fibers requires working memory, as well as understanding plant seasonality and the concept of numbers. Also, such cords are the building blocks for creating other textiles, such as baskets, fabrics, and nets. Once adopted, these objects would have been indispensable in daily life.

This little piece of string provides unprecedented insight into the lives of our extinct relatives, which, despite an abundance of genetic, archaeological, and skeletal data, have been extremely difficult to interpret. It seems as though we humans arent as unique as we like to think.

View post:
Sick bees social distance, but only within their own colony - Massive Science

Skin Stem Cells Comments Off on Sick bees social distance, but only within their own colony – Massive Science | June 4th, 2020

Not anymore.

Thanks to significant philanthropic support from The Sprout Foundation, a Denver-area foundation funded by Suzanne and Bob Fanch, and gifts from others including Wag and Annalee Schorr, the Ehlers-Danlos Syndrome Center of Excellence was launched in 2019. The goal of the center is to eventually develop a cure for EDS at the Gates Center for Regenerative Medicine, while better addressing the clinical needs of patients today through specialty care at Childrens Hospital Colorado. The clinical components of this new center address the critical need for patient-centered, coordinated EDS care where physicians come together to agree on the treatment plan, rather than leaving the patient and their family to determine the course of action.

Calla Winchell, left, with her grandfather, Dr. Wag Schorr, and her mother, Dr. Kate Schorr.

Simultaneously, the Gates Center for Regenerative Medicine scientists are conducting leading-edge research with the ultimate goal of finding a cure. Today, this research is aimed at discovering the genetic underpinnings of hypermobile EDS and leveraging this information to develop future therapies for patients like Calla.

The Fanches said, Sprout Foundation has funded research and the outstanding staff at the Gates Center for Regenerative Medicine to accelerate the cure for this life-changing disorder and also for clinical care to patients through the EDS Center of Excellence.

Joining in this effort are Callas own grandparents, Wag Schorr, an accomplished nephrologist and 1963 CU School of Medicine alumnus, and his wife, Annalee.

An essential component of the EDS Center of Excellence is a translational research program, which leverages existing campus resources and partnerships, including the Gates Center for Regenerative Medicine and the Colorado Center for Personalized Medicine.

The research program at the Gates Center is led by Dennis Roop, PhD, director of the Gates Center, in partnership with Ganna Bilousova, PhD, and Igor Kogut, PhD. The program brings EDS patients genetic information from clinical visits to the Gates Center where researchers are working on future treatments for the condition. In this virtuous cycle, patients inform future therapies in the lab that, in turn, could ultimately change lives back in the clinic.

Calla is one of those patients. She is motivated by the possibility of improving EDS research.

In preclinical models, scientists are collecting stem cells from Calla and other patients that indicate a possible mutation. These studies, using multiple patients, allow for a more accurate portrait of the errors in DNA. Early findings at the Gates Center suggest that a possible mutation for the hypermobile form of EDS may have been identified. The hope is that this research will lead to a potential treatment in the coming years.

Scientists are growing skin cells in the lab using Callas stem cells, with the EDS gene mutations removed. If successful, the modified stem cells will hook onto sites of inflammation and grow new cells restoring function to damaged tissues and organs. It sounds like science fiction, but it could be a reality at the CU Anschutz Medical Campus in the years to come.

The research advances taking place at the Gates Center will ultimately mean incredible hope and healing for people like Calla, and others with rare genetic disorders, who are eager to regain their health and their independence.

Im thrilled, she said. Im excited to receive coordinated care and treatments that will help me get back to my life. What if I could go to the grocery store and not have to use a wheelchair anymore?

By bringing research together with clinical care, the EDS Center of Excellence is helping turn such possibilities into realities.

Callas care plan is coordinated by a team of experts at the EDS multidisciplinary clinic at Childrens Hospital Colorado, led by the Medical Director of the Special Care Clinic Ellen Roy Elias, MD, in close collaboration with Kourtney Santucci, MD.

The clinic places the patient at the center of care, and brings forward all of the right health professionals required to determine a comprehensive care plan. In this model, the patient is seen by a team of specialists in a single day, with the goal of having a treatment plan at the end of the visit.

Callas grandfather, Dr. Schorr, says no more will Calla and others like her have to create a center of excellence for themselves as they traverse a complex and fragmented healthcare system to ensure their needs are met.

The pioneering work taking place at the EDS Center of Excellence began with Dr. Schorrs vision. In 2016, as a member of the Gates Center for Regenerative Medicine Advisory Board, Dr. Schorr approached director Dennis Roop and began laying the groundwork for research efforts in EDS, which he and Annalee funded later that year. Dr. Schorrs vision and commitment made it possible to develop the EDS Center of Excellence as a place to realize scientific advances in EDS research.

CU is poised for another breakthrough in medicine, said Dr. Schorr. I believe that EDS patients will soon have access to effective treatments, and possibly even a cure. If we are precise with our research and resources, we can resume our place at the forefront of the medical world. Thats our responsibility.

Another must, said Dr. Schorr, is to empower visionaries in their fields to pave the path toward new discoveries and major medical advances.

Leading this charge is CU School of Medicine Dean and Vice Chancellor for Health Affairs John Reilly, Jr., MD. Dean Reilly said, One of the great advantages of having our pediatric hospital partner, Childrens Hospital Colorado, and a research entity like the Gates Center on campus is the opportunity to collaborate. By bringing some of the best minds together to lead the next generation in EDS research, we get remarkable innovation, and leading-edge treatments and care. What our philanthropic partners have built here is inspiring, and together we are determined to bring hope to patients and their families. It has been exciting to see two families with a long friendship come together with a shared goal to create a center that will have a positive effect on so many patients and families.

With each new discovery at the EDS Center of Excellence, lives will improve through better care and better health. Each new discovery brings new opportunity for people with EDS to live lives they never knew they could have.

Guest Contributor: Courtney Keener, CU Anschutz Office of Advancement.

Continued here:
Hope Realized - CU Anschutz Today

Skin Stem Cells Comments Off on Hope Realized – CU Anschutz Today | June 3rd, 2020

(MENAFN - GetNews) Market Research Future (MRFR) collected data on several factors including implications of COVID 19 Impact on Regenerative Medicine Market and demographic challenges, showed how it could move forward in the coming years.

Regenerative Medicine Market Outlook

Global regenerative medicine market is growing continually, witnessing a massive uptake. Market growth primarily attributes to the increasing advancement in healthcare technology and the growing prevalence of chronic diseases. Besides, improvements in the field of regenerative medicine and stem cell technology drive the growth of the market excellently.

Moreover, the rising uptake of therapeutics such as stem cell biology, cellular therapy, tissue engineering in applications, including cord blood, oncology, urology, orthopedics, neurology, dermatology, and others accelerate the market growth. According to Market Research Future (MRFR), the global regenerative medicine market is poised to grow at 25.4% CAGR throughout the forecast period (2016 2022).

Get a FREE Sample (Including COVID19 Impact Analysis, Full TOC, Tables and Figures) ofRegenerative Medicine Market@ https://www.marketresearchfuture.com/sample_request/2220

Additionally, the rising uptake of stem cell & tissue engineering processes in the treatment of health issues ranging from orthopedics, musculoskeletal & spine, dental, and skin/integumentary to cancer, neurology, and cardiology substantiate the market growth. Furthermore, the increasing rate of road accidents, injuries, and trauma cases drive the market exponentially, driving the demand for transplants & surgical reconstruction procedures.

On the other hand, factors such as the lack of awareness, skilled professionals, and stringent regulatory policies are projected to act as significant impeders for market growth. Nevertheless, funding support for the development of regenerative medicines would support the growth of the market throughout the predicted period. Also, widening application areas of regenerative medicines in the field of stem cell reconstructive and skin grafting would increase the market growth.

Global Regenerative Medicine Market Segments

The analysis is segmented into four dynamics;

By Material : Synthetic Materials, Genetically Engineered Materials, Pharmaceuticals, and others.

By Therapy : Stem Cell Biology, Cellular Therapy, Tissue Engineering, and others.

By Application : Cord Blood, Oncology, Urology, Orthopedics, Neurology, Dermatology, and others.

By Regions : Americas, Europe, Asia Pacific, Middle East & Africa, and Rest-of-the-World.

Regenerative Medicine Market Regional Analysis

North America is projected to continue dominating the global regenerative medicine market throughout the forecast period. In 2015, North America accounted for more than 44% of the overall market share. This huge market growth attributes to the presence of a large number of major players and pharma & biotechnology companies. Moreover, huge investments made by public & private organizations drive the regenerative medicine industry in the region.

Besides, the rising prevalence of chronic diseases and orthopedic issues and increasing clinical trials to evaluate the therapeutic potential of products foster regional market growth. Also, the well-spread awareness towards the therapeutic potency of regenerative medicines impacts the market growth positively. The North American regenerative medicine market is expected to grow at a robust CAGR of 22.3% over the review period.

Europe stands second in the global regenerative medicine market. Factors such as the increasing per capita healthcare expenses and penetration of healthcare sectors in the region boost the market growth. Additionally, the rising government support and R & D funding in the life science developments substantiate the regional market growth. Markets in the UK, Germany, and France, contribute to the regional market majorly. The European regenerative medicine market is estimated to grow at 22.5% CAGR during the assessment period.

The Asia Pacific regenerative medicine market has emerged as a rapidly growing market. Factors such as the large advances in biotechnology and increasing government support for R & D are fostering the growth of the regional market. Regenerative medicine markets in highly populated countries such as China, India, and Japan support the regional market growth excellently, heading with huge technological advances. The APAC Regenerative Medicine market is predicted to demonstrate huge growth potential.

Global Regenerative Medicine Market - Competitive Analysis

The well-established regenerative medicine market appears to be highly competitive with the presence of several notable players. To gain a larger competitive advantage, market players incorporate strategic initiatives such as mergers & acquisitions, expansions, and product/technology launch. Also, they make substantial investments to drive R & D to develop their capabilities and to expand their global footprints. Simultaneously, R & D funding programs initiated by the governments to enhance regenerative medicine capabilities are offering high growth potential. This is further going to attract several new entrants to the market and intensify the market competition further.

Regenerative Medicine Market Major Players:

Players active in the global regenerative medicine market include Osiris Therapeutics, Cook Biotech, Organogenesis, Baxter International, Inc., Stryker and RTI surgical, LifeSciences, CryoLife, Advanced Cell Technology, Sanofi, BioMimetic Therapeutics, Medtronic, StemCellsInc, and LifeCell Kinetic Concepts, among others.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220

Regenerative Medicine Industry/Innovations/Related News:

March 15, 2020 - Research team at the University of Sheffield published their study on stem cell mutations that could improve regenerative medicine in the magazine Stem Cell Reports.' Their study gives new insights into the cause of mutations in pluripotent stem cells and potential ways of stopping these mutations from occurring. It also suggests ways to reduce the likelihood of variations occurring in these cells when cultured.There is considerable interest in using Pluripotent stem cells to produce cells that can replace diseased or damaged tissues in applications referred to as regenerative medicine.

Pharmaceutical Industry Related Reports

Global Anti-viral drugs Market Information, by application (hepatitis, HIV/AIDS, herpes, influenza and others) and by mechanism of action (nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others) - Forecast to 2022: https://www.marketresearchfuture.com/reports/anti-viral-drugs-market-2454

Drug allergy market information: by type (immunologic, nonimmunologic, and others), diagnosis (skin tests, blood tests, and others), by treatment (antihistamines, corticosteroids, and others), by end user- global forecast till 2023: https://www.marketresearchfuture.com/reports/drug-allergy-market-4033

About Market Research Future:

At Market Research Future (MRFR) , we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Media Contact Company Name: Market Research Future Contact Person: Abhishek Sawant Email: Send Email Phone: +1 646 845 9312 Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar City: Pune State: Maharashtra Country: India Website: http://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220

MENAFN0206202000703268ID1100263430

Continued here:
Impacts of COVID 19 on the Global Regenerative Medicine Market Size: Global Industry Analysis, Growth, Top Companies Revenue, MRFR Reveals Insights...

Skin Stem Cells Comments Off on Impacts of COVID 19 on the Global Regenerative Medicine Market Size: Global Industry Analysis, Growth, Top Companies Revenue, MRFR Reveals Insights… | June 3rd, 2020

Research focuses on mans exposure prior to conception

A new study from the University of Georgia has shown that exposure to a now-banned flame retardant can alter the genetic code in sperm, leading to major health defects in children of exposed parents.

Published recently in Scientific Reports, the study is the first to investigate how polybrominated biphenyl-153 (PBB153), the primary chemical component of the flame retardant FireMaster, impacts paternal reproduction.

In 1973, an estimated 6.5 million Michigan residents were exposed to PBB153 when FireMaster was accidentally sent to state grain mills where it made its way into the food supply. In the decades since, a range of health problems including skin discoloration, headache, dizziness, joint pain and even some cancers have been linked to the exposure.

More striking, the children of those who were exposed seemed to experience a host of health issues as well, including reports of hernia or buildup in the scrotum for newborn sons and a higher chance of stillbirth or miscarriage among adult daughters.

Yet, little work has been done to understand how the chemical exposure could have impacted genes passed from an exposed father, said study author Katherine Greeson.

It is still a relatively new idea that a mans exposures prior to conception can impact the health of his children, said Greeson, an environmental health science doctoral student in Charles Easleys lab at UGAs College of Public Health and Regenerative Bioscience Center.

Most studies where a toxic effect is observed in children look only to the mothers and the same has been true of studies conducted on PBB153, she said.

Greeson and a team of researchers from UGA and Emory University used a unique combination of observational and laboratory approaches to demonstrate how PBB153 acted on sperm cells.

Typically, scientific studies are either epidemiological in nature and inherently observational or focus on bench science, but in this study, we did both, said Greeson.

This approach allowed the researchers to mimic the known blood exposure levels of PBB153 in a lab environment.

We were uniquely able to recreate this effect using our previously characterized human stem cell model for spermatogenesis, she said, which allowed us to study the mechanism that causes this effect in humans.

The team looked at the expression of different genes in their human spermatogenesis model after dosing with PBB153 and found marked alterations in gene expression between dosed and undosed cells, specifically at genes important to development, such as embryonic organ, limb, muscle, and nervous system development.

PBB153 causes changes to the DNA in sperm in a way that changes how the genes are turned on and off, said Greeson. PBB153 seems to turn on these genes in sperm which should be turned off, said Greeson, which may explain some of the endocrine-related health issues observed in the children of exposed parents.

Though the study used this model to directly replicate exposure to PBB153, Greeson says this approach could be used to better understand the impact of other environmental exposures on reproduction, including large-scale accidental exposures to toxic chemicals or everyday exposures.

Hopefully this work will lead to more studies combining epidemiology and bench science in the future, which will tell us more about why were seeing an effect from an environmental exposure in human populations and encourage experimental studies to more closely mimic human exposures, she said.

The study, Detrimental Effects of Flame Retardant, PBB153, Exposure on Sperm and Future Generations, published May 22. It is available online.

Excerpt from:
Study reveals birth defects caused by flame retardant - University of Georgia

Skin Stem Cells Comments Off on Study reveals birth defects caused by flame retardant – University of Georgia | June 3rd, 2020

Skin Stem Cells Comments Off on Buckeye butterflies get their color from their scales – Massive Science | June 3rd, 2020

DetailsCategory: DNA RNA and CellsPublished on Wednesday, 03 June 2020 09:39Hits: 306

Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)

SEATTLE, WA and KING of PRUSSIA, PA, USA I June 2, 2020 I Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.

Initially, the alliance will focus on the development of treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome and X-linked Agammaglobulinemia. These are two of more than 400 identified primary immunodeficiency diseases in which a part of the body's immune system is missing or functions improperly.

"CSL Behring will collaborate with Seattle Children's experts to apply our novel gene therapy technology to their research pipeline, with an aim to address unmet needs for people living with certain rare primary immunodeficiency diseases," said Bill Mezzanotte, MD, Executive Vice President, Head of Research and Development for CSL Behring. "Expanding our gene therapy portfolio into an area of immunology well known to CSL exemplifies how we are strategically growing our capabilities in this strategic scientific platform and are collaborating with world class institutions to access innovation with the potential to vastly improve patients' lives."

"Stem cell gene therapies that correct the genetic abnormality driving a child's disease will transform the therapeutic options for children with Wiskott-Aldrich Syndrome, X-Linked Agammaglobulinemia and other immunodeficiency diseases,"said David J. Rawlings, MD, director of the Center for Immunity and Immunotherapies and division chief of immunology at Seattle Children's, and a professor of pediatrics and immunology at the University of Washington School of Medicine."The collaboration with CSL Behring supports our longstanding research programs for pediatric immunodeficiency diseases and will accelerate this research toward clinical trials, helping get these innovations to the children who need them."

CSL Behring researchers, working with researchers from Seattle Children's Research Institute, will investigate applying the proprietary platform technologies, Select+ and Cytegrity, to several pre-clinical gene therapy programs. These technologies, which have broad applications in ex vivo stem cell gene therapy, are designed to address some of the major challenges associated with the commercialization of stem cell therapy, including the ability to manufacture consistent, high-quality products, and to improve engraftment, efficacy and tolerability.

Wiskott-Aldrich Syndrome (WAS) has an estimated incidence between one and 10 cases per million males worldwide, according to the National Institutes of Health. WAS patients' immune systems function abnormally, making them susceptible to infections. They also experience eczema, autoimmunity and difficulty forming blood clots, leaving them vulnerable to life threatening bleeding complications. Today the only knowncurefor WAS is a stem cell transplant, if a suitable donor can be found.

X-linked Agammaglobulinemia (XLA) is another rare primary immunodeficiency in which patients have low levels of immunoglobulins (also known as antibodies), which are key proteins made by the immune system to help fight infections. Like WAS, XLA affects males almost exclusively, although females can be genetic carriers of the condition. While no cure exists for XLA, the goal of treatment is to boost the immune system by replacing missing antibodies and preventing or aggressively treating infections that occur, according to the Immune Deficiency Foundation.

About Seattle Children's

Seattle Children's mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children's Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children's hospitals in the country by U.S. News & World Report, Seattle Children's serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho the largest region of any children's hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children's Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children's Hospital and Research Foundation works with the Seattle Children's Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children's bold initiative It Starts With Yes: The Campaign for Seattle Children's to transform children's health for generations to come.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, and delivers its life-saving therapies to people in more than 70 countries. For more information, visit http://www.cslbehring.com and for inspiring stories about the promise of biotechnology, visit Vita http://www.cslbehring.com/Vita.

SOURCE: CSL Behring

See more here:
CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases | DNA RNA and Cells |...

Cardiac Stem Cells Comments Off on CSL Behring and Seattle Children’s Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases | DNA RNA and Cells |… | June 3rd, 2020

GAITHERSBURG, Md., June 03, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that its strategic collaboration with the New York State Department of Health (DOH) to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide is entering into its second year expansion phase. Having successfully achieved all of the milestones of the first year pilot phase for the development of an infectious disease digital health and precision medicine platform that connects healthcare institutions to DOH and uses genomic microbiology for statewide surveillance and control of antimicrobial resistance, OpGen will continue to work together with DOHs Wadsworth Center, participating healthcare systems, and collaborators such as Infectious Disease Connect, Inc. (IDC), which recently combined with ILM Health Solutions, to expand the reach of the platform, increase the volume of testing, and enhance data collection.

The DOH, OpGen, IDC and all stakeholders will continue to work collaboratively to demonstrate that a sustainable, flexible infectious diseases reporting, tracking and surveillance tool for antimicrobial resistance can be applied across New York State. The second-year expansion phase will build on the successes and experience of the first year pilot phase while focusing on accomplishing the goal of this visionary effort to improve patient outcomes and save healthcare dollars by integrating real-time epidemiologic surveillance with rapid delivery of antibiotic resistance results to care-givers via web-based and mobile platforms. OpGen is providing its Acuitas AMR Gene Panel for rapid detection of multidrug-resistant bacterial pathogens along with its Acuitas Lighthouse Software for high resolution pathogen tracking. The second year contract includes a quarterly retainer-based project fee as well as volume-dependent per test fees for a total contract value of up to $450,000 to OpGen.

We are excited and grateful that despite the continued threat of the COVID-19 pandemic which has hit New York State harder than any other place in the world, the Department of Health of New York State and the Wadsworth Center continue to work with us and have expanded their partnership for a second year, adding up to 3,500 AMR Gene Panel tests to be run, commented Oliver Schacht, CEO of OpGen. The quick spread of antimicrobial resistant superbugs across our healthcare systems is lurking below the current medical crisis. We anticipate that with our innovative diagnostic solutions we will be able to proactively identify such pathogens leading to early intervention and lifesaving treatment. A further project expansion of this nature may include the exploration of ways to achieve SARS-CoV-2 tracking.

Paul Edwards, Chief Strategy Officer at IDC commented, Our collaboration with OpGen allows us to not only identify bacteria and antimicrobial resistance down to the gene level but also to identify new or significant results versus phenotypic results alone. This molecular epidemiology capability in turn is critical in order to rapidly identify new clusters and outbreaks which otherwise would be missed and could potentially lead to outbreaks of hospital superbugs.

The precision medicine solutions provided by OpGen to accomplish the project goals are:

Wadsworth Center Director Dr. Jill Taylor said,"Under Governor Cuomo's leadership, New York State continues to lead the nation in addressing the threat of antimicrobial resistance. Working with our private-sector partners, the Wadsworth Center is able to further advance our mission to improve the public health of all New Yorkers.

About Antimicrobial-resistant InfectionsThe Centers for Disease Control and Prevention estimates that annually in the United States we face 2.8 million infections with 35,000 deaths and $49 billion in lost productivity all attributable to antibiotic resistant infections. Among the infectious diseases the parties are working to address are carbapenem-resistant Enterobacteriaceae (CRE) bacteria; they are untreatable and hard-to-treat infections on the rise among patients in medical facilities. CREs have become resistant to all or nearly all the antibiotics we have today. Almost half of hospital patients who get bloodstream infections from CRE bacteria die from the infection. The CDC has classified CREs as one of three urgent threats to the public health.

About Wadsworth Center LaboratoriesThe Wadsworth Center laboratories stand at the forefront of biomedical and environmental sciences and their interplay. The Center serves a vital role in the New York State Department of Healths efforts to protect and promote the health of New Yorks citizens. Building on more than a century of excellence as the states public health laboratory, the Center continues as a premier biomedical institute that merges clinical and environmental testing with fundamental, applied and translational research. Today, Wadsworth Center scientists use both classical and contemporary approaches to study environmental and biological questions related to human health and disease. They develop advanced methods to identify microbial or chemical threats; study drug resistance, emerging infections, and environmental exposures; manage the countrys most comprehensive diagnostic and environmental testing laboratory permit program; oversee extramural research programs on stem cells, breast cancer and spinal cord injury; and train the next generation of scientists through undergraduate, graduate, postdoctoral and visiting scientist programs.

About OpGen Inc.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGens product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit http://www.opgen.com.

Forward-Looking Statements

This press release includes statements regarding OpGens second year project phase with the New York State DOH. These statements and other statements regarding OpGens future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, our ability to successfully complete the second phase of the project with the New York State DOH, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Companys operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen:Oliver SchachtPresident and CEO[emailprotected]

OpGen Press Contact:Matthew BretziusFischTank PR[emailprotected]

OpGen Investor Contact:Joe GreenEdison Group[emailprotected]

View original post here:
OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections - GuruFocus.com

Spinal Cord Stem Cells Comments Off on OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections – GuruFocus.com | June 3rd, 2020

People usually volunteer to donate stem cells for an allogeneic transplant either because they have a loved one or friend who needs a match or because they want to help people. Some people give their stem cells so they can get them back later if they need an autologous transplant.

People who want to donate stem cells or join a volunteer registry can speak with a health care provider or contact the National Marrow Donor Program to find the nearest donor center. Potential donors are asked questions to make sure they are healthy enough to donate and dont pose a risk of infection to the recipient. For more information about donor eligibility guidelines, contact Be the Match or the donor center in your area.

Be the Match (formerly the National Marrow Donor Program)Toll-free number: 1-800-MARROW-2 (1-800-627-7692)Website: http://www.bethematch.org

A simple blood test is done to learn the potential donors HLA type. There may be a one-time, tax-deductible fee of about $75 to $100 for this test. People who join a volunteer donor registry will most likely have their tissue type kept on file until they reach age 60.

Pregnant women who want to donate their babys cord blood should make arrangements for it early in the pregnancy, at least before the third trimester. Donation is safe, free, and does not affect the birth process.

If a possible stem cell donor is found to be a good match for a recipient, steps are taken to teach the donor about the transplant process and make sure he or she is making an informed decision. If a person decides to donate, a consent form must be signed after the risks of donating are fully discussed. The donor is not pressured to take part. Its always a choice.

If a person decides to donate, a medical exam and blood tests will be done to make sure the donor is in good health.

Stem cells may be collected from these 3 different sources:

Each method of collection is explained here.

This process is often called bone marrow harvest. Its done in an operating room, while the donor is under general anesthesia (given medicine to put them into a deep sleep so they dont feel pain). The marrow cells are taken from the back of the pelvic (hip) bone. The donor lies face down, and a large needle is put through the skin and into the back of the hip bone. Its pushed through the bone to the center and the thick, liquid marrow is pulled out through the needle. This is repeated several times until enough marrow has been taken out (harvested). The amount taken depends on the donors weight. Often, about 10% of the donors marrow, or about 2 pints, are collected. This takes about 1 to 2 hours. The body will replace these cells within 4 to 6 weeks. If blood was taken from the donor before the marrow donation, its often given back to the donor at this time.

After the bone marrow is harvested, the donor is taken to the recovery room while the anesthesia wears off. The donor may then be taken to a hospital room and watched until fully alert and able to eat and drink. In most cases, the donor is able to leave the hospital within a few hours or by the next morning.

The donor may have soreness, bruising, and aching at the back of the hips and lower back for a few days. Over-the-counter pain medications or nonsteroidal anti-inflammatory drugs are helpful. Some people may feel tired or weak, and have trouble walking for a few days. The donor might be told to take iron supplements until the number of red blood cells returns to normal. Most donors get back to their usual activities in 2 to 3 days. But it could take 2 or 3 weeks before they feel completely back to normal.

There arent many risks for donors and serious complications are rare. But bone marrow donation is a surgical procedure. Rare complications could include anesthesia reactions, infection, nerve or muscle damage, transfusion reactions (if a blood transfusion of someone elses blood is needed this doesnt happen if you get your own blood), or injury at the needle insertion sites. Problems such as sore throat or nausea may be caused by anesthesia.

Allogeneic stem cell donors do not have to pay for the harvesting because the recipients insurance company usually covers the cost. Even so, be sure to ask about insurance coverage before you decide to have the bone marrow harvest done.

Once the cells are collected, they are filtered through fine mesh screens. This prevents bone or fat particles from being given to the recipient. For an allogeneic or syngeneic transplant, the cells may be given to the recipient through a vein soon after they are harvested. Sometimes theyre frozen, for example, if the donor lives far away from the recipient.

For several days before starting the donation process, the donor is given a daily injection (shot) of a drug that causes the bone marrow to make and release a lot of stem cells into the blood. Filgrastim can cause some side effects, the most common being bone pain and headaches. These may be helped by over-the-counter pain medications or nonsteroidal anti-inflammatory drugs. Nausea, sleeping problems, low-grade (mild) fevers, and tiredness are other possible effects. These go away once the injections are finished and collection is completed.

After the shots, blood is removed through a catheter (a thin, flexible plastic tube) thats put in a large vein in the arm. Its then cycled through a machine that separates the stem cells from the other blood cells. The stem cells are kept while the rest of the blood is returned to the donor, often through the same catheter. (In some cases, a catheter may be put in each arm one takes out blood and the other puts it back.) This process is called apheresis. It takes about 2 to 4 hours and is done as an outpatient procedure. Often the process needs to be repeated daily for a few days, until enough stem cells have been collected.

Possible side effects of the catheter can include trouble placing the catheter in the vein, blockage of the catheter, or infection of the catheter or at the area where it enters the vein. Blood clots are another possible side effect. During the apheresis procedure, donors may have problems caused by low calcium levels from the anti-coagulant drug used to keep the blood from clotting in the machine. These can include feeling lightheaded or tingly, and having chills or muscle cramps. These go away after donation is complete, but may be treated by giving the donor calcium supplements.

The process of donating cells for yourself (autologous stem cell donation) is pretty much the same as when someone donates them for someone else (allogeneic donation). Its just that in autologous stem cell donation the donor is also the recipient, giving stem cells for his or her own use later on. For some people, there are a few differences. For instance, sometimes chemotherapy (chemo) is given before the growth factor drug is used to tell the body to make stem cells. Also, sometimes it can be hard to get enough stem cells from a person with cancer. Even after several days of apheresis, there may not be enough for the transplant. This is more likely to be a problem if the patient has had certain kinds of chemo in the past, or if they have an illness that affects their bone marrow.

Cord blood is the blood thats left in the placenta and umbilical cord after a baby is born. Collecting it does not pose any health risk to the infant or the mother. Cord blood transplants use blood that would otherwise be thrown away. After the umbilical cord is clamped and cut, the placenta and umbilical cord are cleaned. The cord blood is put into a sterile container, mixed with a preservative, and frozen until needed.

Some parents choose to donate their infants cord blood to a public blood bank, so that it may be used by anyone who needs it. Many hospitals collect cord blood for donation, which makes it easier for parents to donate. Parents can donate their newborns cord blood to volunteer or public cord blood banks at no cost. For more about donating your newborns cord blood, call 1-800-MARROW2 (1-800-627-7692) or visit Be the Match.

Other parents store their newborns cord blood in private cord blood banks just in case the child or a close relative needs it someday. If you want to donate or bank (save) your childs cord blood, youll need to arrange it before the baby is born. Some banks require you to set it up before the 28th week of pregnancy, although others accept later setups. Among other things, youll be asked to answer health questions and sign a consent form.

Parents may want to bank their childs cord blood if the family has a history of diseases that may benefit from stem cell transplant. There are several private companies offer this service. But here are some things to think about:

More information on private family cord blood banking can be found at the Parents Guide to Cord Blood Foundation. You can visit their website at http://www.parentsguidecordblood.org.

Read the rest here:
Donating Stem Cells and Bone Marrow

Bone Marrow Stem Cells Comments Off on Donating Stem Cells and Bone Marrow | June 3rd, 2020

Mesenchymal Stem Cells Market Trends by Manufacturers, States, Type and Application, Forecast to 2019 2027

Global Mesenchymal Stem Cells Market: Snapshot

The increasing use of mesenchymal stem cells (MSCs) for the treatment of diseases and disabilities of the growing aging population is having a positive influence on the global mesenchymal stem cells market. Mesenchymal stem cells are adult stem cells that are of various types such as adipocytes, osteocytes, monocytes, and chondrocytes.

The main function of mesenchymal stem cells is to replace or repair damaged tissue.

Report Overview @www.transparencymarketresearch.com/mesencharket.html

Mesenchymal stem cells are multipotent, i.e. they can produce more than one type of specialized cells.

These specialized cells have their own distinguishing shapes, structures, and functions, with each of them belonging to a particular tissue.

Mesenchymal stem cells are traditionally found in the bone marrow. However, these cells can also be separated from other tissues such as cord blood, fallopian tube, peripheral blood, and fetal liver and lung.

Mesenchymal stem cells have long thin cell bodies containing a large nucleus. MSCs have enormous capacity for renewal keeping multipotency.

Due to these virtues, mesenchymal stem cells have huge therapeutic capacity for tissue repair.

Get Brochure of the Report @www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells can differentiate into a number of cell types that belong to our skeletal tissues that include cartilage, bone, and fat. Research is underway to discover if mesenchymal stem cells can be used to treat bone and cartilage diseases.

Scientists are also exploring the possibility if mesenchymal stem cells differentiate into other type of cells apart from skeletal tissues. This includes nerve cells, liver cells, heart muscle cells, and endothelial cells.

This will lead to mesenchymal stem cells to be used to treat other diseases.

Stem cells are specialized cells which have the capability of renewing themselves through cell division and differentiate into multi-lineage cells. Mesenchymal stem cells (MSCs) are non- hematopoietic, multipotent adult stem cells which can be isolated from bone marrow, cord blood, fat tissue, peripheral blood, fallopian tube, and fetal liver and lung tissue.

Request For Covid19 Impact Analysis http://www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells have the capacity to differentiate into mesodermal lineages, such as chondrocytes, adipocytes, and osteocytes, and non-mesodermal lineages such as ectodermal (neurocytes) and endodermal lineages (hepatocytes). These stem cells have specific features such as multilineage potential, secretion of anti-inflammatory molecules, and immunomodulation.

These cells have emerged as promising therapeutic agents for regenerating skeletal tissues such as damaged bone and cartilage tissues and treatment of chronic diseases owing to their specific features.

The global mesenchymal stem cells market is expected to be driven by the increasing clinical application of mesenchymal stem cells for the treatment of chronic diseases, bone and cartilage diseases, and autoimmune diseases. Studies have shown that these stem cells enhance the angiogenesis in myocardium and allow the reduction of myocardial fibrotic area.

The pre-clinical studies for using mesenchymal stem cells in treatment of cardiovascular diseases, liver diseases, and cancer are projected to create new market opportunities for mesenchymal stem cells. Mesenchymal stem cells also produce anti-inflammatory molecules which modulate humoral and cellular immune responses.

Features of these stem cells such as ease of isolation, regenerative potential, and immunoregulatory, the mesenchymal stem cell therapy has emerged as a promising tool for the treatment of chronic diseases, degenerative, inflammatory, and autoimmune diseases.

Pre Book Now @www.transparencymarketresearch.com/checkoump;ltype=S

Clinical studies are exploring MSCs for various conditions such as orthopedic injuries, graft versus host disease following bone marrow transplantation, and genetic modification of MSCs to overexpress antitumor genes for use as anticancer therapy, which are exhibiting new opportunities in therapeutic area. However, the mesenchymal stem cell research studies are tedious, lengthy, and complex.

In some cases, due to some adverse effects transplanted mesenchymal stem cells rapidly removed from the body which limits use of stem cells in therapeutic treatments. The conflicting results and regulatory compliances for approvals may also hamper the growth of this market.

The global mesenchymal stem cells market is segmented on the basis of source of isolation, end-user, and region. Stem cells are isolated from the bone marrow, peripheral blood, lung tissue, umbilical cord blood, amniotic fluids, adipose tissues, and synovial tissues.

Traditionally the MSCs were isolated from bone marrow aspiration which is associated with risk of infection and painful for the patient. The MSCs from adipose tissues are usually isolated from the biological material generated during liposuction, lipectomy procedures by using collagenase enzymatic digestion followed by centrifugation and washing.

In terms of end-user, the market is segmented into clinical research organizations, biotechnological companies, medical research institutes, and hospitals.

Read our Case study at :www.transparencymarketresearch.com/casestug-start-up

Geographically, the global mesenchymal stent cells market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to continue its dominance in terms of market share during the forecast period owing to high R&D expenditure, availability of advanced research facilities and skilled professionals, and government initiatives.

Europe is the second largest market after North America. The Asia Pacific market is projected to expand at a high CAGR during the forecast period due to increased R&D budgets in Japan, China, and India.

Key global players operating in the mesenchymal stem cells market include R&D Systems, Inc., Cell Applications, Inc., Axol Bioscience Ltd., Cyagen Biosciences Inc., Cytori Therapeutics Inc., Stemcelltechnologies Inc., BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc., and Celprogen, Inc.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read this article:
Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 - WhaTech Technology and Markets News

Bone Marrow Stem Cells Comments Off on Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 – WhaTech Technology and Markets News | June 3rd, 2020